Major impact of hormonal therapy in localized prostate cancer - Death can already be an exception

Journal of Steroid Biochemistry and Molecular Biology

Volumn 92, Issue 5, 2004, Pages 327-344

  Labrie, Fernand ^a   Cusan, Leonello ^a   Gomez, José ^a   Luu The, Van ^a   Candas, Bernard ^a   Bélanger, Alain ^a   Labrie, Claude ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Androgens; Combined androgen blockade; Early diagnosis; Intracrinology; LHRH agonists; Localized disease; Monotherapy; Prostate cancer; Pure antiandrogens

Indexed keywords

ANTHRACYCLINE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BUSERELIN; CHLORMADINONE ACETATE; CYPROTERONE ACETATE; FLUTAMIDE; GLUCURONOSYLTRANSFERASE; GONADORELIN AGONIST; IRINOTECAN; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NAVELBINE; NILUTAMIDE; PRASTERONE; RALOXIFENE; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CASTRATION; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART DISEASE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LIBIDO DISORDER; LUNG CANCER; META ANALYSIS; NONHUMAN; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; POTENCY DISORDER; PROSTATE CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STEROIDOGENESIS;

ANIMALS; HORMONES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 13244249869     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.10.011     Document Type: Review

References (107)

1. A. Jemal, T. Murray, A. Samuels, A. Ghafoor, E. Ward, and M.J. Thun Cancer Statistics 2003 CA Cancer J. Clin. 53 2003 5 26
2. F. Labrie, A. Dupont, and A. Bélanger Complete androgen blockade for the treatment of prostate cancer V.T. de Vita S. Hellman S.A. Rosenberg Important Advances in Oncology 1985 J.B. Lippincott Philadelphia 193 217
3. C. Labrie, A. Bélanger, and F. Labrie Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate Endocrinology 123 1988 1412 1417
4. F. Labrie Intracrinology Mol. Cell. Endocrinol. 78 1991 C113 C118
5. F. Labrie, V. Luu-the, C. Labrie, A. Bélanger, J. Simard, S.-X. Lin, and G. Pelletier Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone Endocr. Rev. 24 2003 152 182
6. I. Dufort, P. Rheault, X.F. Huang, P. Soucy, and V. Luu-The Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase Endocrinology 140 1999 568 574
7. G. Pelletier, V. Luu-The, M. El-Alfy, S. Li, and F. Labrie Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland J. Mol. Endocrinol. 26 2001 11 19
8. M. El-Alfy, V. Luu-The, X.F. Huang, L. Berger, F. Labrie, and G. Pelletier Localization of type 5 17β-hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry Endocrinology 140 1999 1481 1491
9. W.M. Geissler, D.L. Davis, L. Wu, K.D. Bradshaw, S. Patel, B.B. Mendoça, K.O. Elliston, J.D. Wilson, D.W. Russel, and S. Andersson Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3 Nat. Genet. 7 1994 34 39
10. P. Nokelainen, H. Peltoketo, R. Vihko, and P. Vihko Expression cloning of a novel estrogenic mouse 17 beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase (m17HSD7), previously described as a prolactin receptor-associated protein (PRAP) in rat Mol. Endocrinol. 12 1998 1048 1059
11. J.L. Napoli 17beta-Hydroxysteroid dehydrogenase type 9 and other short-chain dehydrogenases/reductases that catalyze retinoid, 17beta- and 3alpha-hydroxysteroid metabolism Mol. Cell. Endocrinol. 171 2001 103 109
12. X.Y. He, G. Merz, P. Mehta, H. Schulz, and S.Y. Yang Human brain short chain L-3-hydroxyacyl coenzyme A dehydrogenase is a single-domain multifunctional enzyme. Characterization of a novel 17beta-hydroxysteroid dehydrogenase J. Biol. Chem. 274 1999 15014 15019
13. P. Brereton, T. Suzuki, H. Sasano, K. Li, C. Duarte, V. Obeyesekere, F. Haeseleer, K. Palczewski, I. Smith, P. Komesaroff, and Z. Krozowski Pan1b (17betaHSD11)-enzymatic activity and distribution in the lung Mol. Cell. Endocrinol. 171 2001 111 117
14. K.C. Cheng, P.C. White, and K.N. Qin Molecular cloning and expression of rat liver 3 alpha-hydroxysteroid dehydrogenase Mol. Endocrinol. 5 1991 823 828
15. I. Dufort, Y. Tremblay, A. Bélanger, F. Labrie, and V. Luu-The Isolation and characterization of a stereospecific 3β-hydroxysteroid sulfotransferase (pregnenolone sulfotransferase) cDNA DNA Cell. Biol. 15 1996 481 487
16. R.W. Hudson Comparison of 3 alpha-hydroxysteroid dehydrogenase activities in the microsomal fractions of hyperplastic, malignant and normal human prostatic tissues J. Steroid. Biochem. 20 1984 829 833
17. R. Horton, and R. Lobo Peripheral androgens and the role of androstanediol glucuronide Clin. Endocrinol. Metab. 15 1986 293 306
18. R. Horton Dihydrotestosterone is a peripheral paracrine hormone J. Androl. 13 1992 23 27
19. I. Dufort, F. Labrie, and V. Luu-The Human types 1 and 3 3 alpha-hydroxysteroid dehydrogenases: differential lability and tissue distribution J. Clin. Endocrinol. Metab. 86 2001 841 846
20. F. Labrie, V. Luu-The, S.-X. Lin, J. Simard, and C. Labrie Role of 17β-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues Trends Endoclinol. Metab. 11 2000 421 427
21. V. Luu-The Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase J. Steroid. Biochem. Mol. Biol. 76 2001 143 151
22. S. Andersson Steroidogenic enzymes in skin Eur. J. Dermatol. 11 2001 293 295
23. F. Labrie, A. Bélanger, L. Cusan, and B. Candas Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology J. Clin. Endocrinol. Metab. 82 1997 2403 2409
24. P.I. Mackenzie, I.S. Owens, B. Burchell, K.W. Bock, A. Bairoch, A. Belanger, S. Fournel-Gigleux, M. Green, D.W. Hum, T. Iyanagi, D. Lancet, P. Louisot, J. Magdalou, J.R. Chowdhury, J.K. Ritter, H. Schachter, T.R. Tephly, K.F. Tipton, and D.W. Nebert The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence Pharmacogenetics 7 1997 255 269
25. E. Levesque, D. Turgeon, J.S. Carrier, V. Montminy, M. Beaulieu, and A. Belanger Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase Biochemistry 40 2001 3869 3881
26. G. Pelletier, V. Luu-The, X.F. Huang, H. Lapointe, and F. Labrie Localization by in situ hybridization of steroid 5a-reductase isozyme gene expression in the human prostate and preputial skin J. Urol. 160 1998 577 582
27. X.F. Huang, and V. Luu-The Characterization of the oxidative 3alpha-hydroxysteroid dehydrogenase activity of human recombinant 11-cis-retinol dehydrogenase Biochim. Biophys. Acta 1547 2001 351 358
28. X.-F. Huang, and V. Luu-The Molecular characterization of a first human 3 (alpha-beta)-hydroxysteroid epimerase J. Biol. Chem. 275 2000 29452 29457
29. B. Bélanger, A. Bélanger, F. Labrie, A. Dupont, L. Cusan, and G. Monfette Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men J. Steroid. Biochem. 32 1989 695 698
30. A. Bélanger, J. Couture, S. Caron, R. Roy, Determination of non-conjugated and conjugated steroid level in plasma and prostate after separation of C-18 columns, in: H. Bradlow, L. Castagnetta, S. d'Aquino, F. Labrie (Eds.), Steroid Formation, Degradation and Action in Peripheral, Normal, and Neoplastic Tissue, Ann. N.Y. Acad. Sci. (1990) 251-259.
31. D. Turgeon, J.S. Carrier, E. Levesque, D.W. Hum, and A. Belanger Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members Endocrinology 142 2001 778 787
32. O. Barbier, C. Girard, H. Lapointe, M. El-Alfy, D.W. Hum, and A. Belanger Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry J. Clin. Endocrinol. Metab. 85 2000 4819 4826
33. S.L. MacLeod, S. Nowell, J. Plaxco, and N.P. Lang An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer Ann. Surg. Oncol. 7 2000 777 782
34. A. Gsur, M. Preyer, G. Haidinger, G. Schatzl, S. Madersbacher, M. Marberger, C. Vutuc, and M. Micksche A polymorphism in the UDP- Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk Cancer Epidemiol. Biomarkers Prev. 11 2002 497 498
35. F. Labrie, A. Bélanger, L. Cusan, C. Séguin, G. Pelletier, P.A. Kelly, J.J. Reeves, F.A. Lefebvre, A. Lemay, and J.P. Raynaud Antifertility effects of LHRH agonists in the male J. Androl. 1 1980 209 228
36. F. Labrie, A. Dupont, A. Bélanger, L. Cusan, Y. Lacourcière, G. Monfette, J.G. Laberge, J. Emond, A.T. Fazekas, J.P. Raynaud, and J.M. Husson New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen Clin. Invest. Med. 5 1982 267 275
37. E.D. Crawford, M.A. Eisenberger, D.G. McLeod, J.T. Spaulding, R. Benson, F.A. Dorr, B.A. Blumenstein, M.A. Davis, and P.J. Goodman A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N. Engl. J. Med. 321 1989 419 424
38. L. Denis, J. Carnelro de Moura, A. Bono, R. Sylvester, P. Whelan, D. Newling, and M. Depauw Goserelin acetate and flutamide vs. bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center Urology 42 1993 119 129
39. C.L. Bennett, T.D. Tosteson, B. Schmitt, P.D. Weinberg, M.S. Ernstoff, and S.D. Ross Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using Flutamide Prostate Cancer Prostatic Dis. 2 1999 4 8
40. B. Schmitt, T.J. Wilt, P.F. Schellhammer, V. DeMasi, O. Sartor, E.D. Crawford, and C.L. Bennett Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review Urology 57 2001 727 732
41. L.H. Klotz Combined androgen blockade in prostate cancer: meta-analyses and associated issues BJU Int. 87 2001 806 813
42. A.G. Aprikian, N. Fleshner, A. Langleben, and J. Hames An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer Can. J. Urol. 10 2003 1986 1994
43. L.H. Klotz Selling ourselves short Can. J. Urol. 10 2003 1969
44. R.A. Janknegt, C.C. Abbou, R. Bartoletti, L. Bernstein-Hahn, B. Bracken, J.M. Brisset, F.C. Da Silva, G. Chisholm, E.D. Crawford, F.M.J. Debruyne, G.D. Dijkman, J. Frick, L. Goedhals, H. Knönagel, and P.M. Venner Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial J. Urol. 149 1993 77 83
45. J.F. Caubet, T.D. Tosteson, E.W. Dong, E.M. Naylon, G.W. Whiting, M.S. Ernstoff, and S.D. Ross Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens Urology 49 1997 71 78
46. G.A. Dijkman, R.A. Janknegt, T.M. Dereijke, and F.M.J. Debruyne Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization J. Urol. 158 1997 160 163
47. L.J. Denis, F. Keuppens, P.H. Smith, P. Whelan, J.L. Carneiro de Moura, D. Newling, A. Bono, and R. Sylvester Maximal androgen blockade: final analysis of EORTC Phase III trial 30853 Eur. Urol. 33 1998 144 151
48. Prostate Cancer Triallists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Lancet 355 2000 1491 1498
49. F. Debruyne, P. Delaere, and V. Vander Poorten Postoperative course of serum parathyroid hormone and calcium after surgery for primary hyperparathyroidism Acta Otorhinolaryngol. Belg. 55 2001 153 157
50. K.J. Graf, R.L. Kleinecke, and F. Neumann The stimulation of male duct derivatives in female guinea-pig with an antiandrogen, cyproterone acetate J. Reprod. Fertil. 39 1974 311 317
51. M. Plante, S. Lapointe, and F. Labrie Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice J. Steroid. Biochem. 31 1988 61 64
52. F. Labrie, and B. Candas Androgen blockade in prostate cancer (Letter-to-the-Editor) Lancet 356 2000 341 342
53. M. Laufer, S.R. Denmeade, V.J. Sinibaldi, M.A. Carducci, and M.A. Eisenberger Complete androgen blockade for prostate cancer: what went wrong? J. Urol. 164 2000 3 9
54. D. Raghavan Systemic therapy for advanced prostate cancer J. Clin. Oncol. 17 1999 494 501
55. B. Schmitt, C. Bennett, J. Seidenfeld, D. Samson, and T. Wilt Maximal androgen blockade for advanced prostate cancer Cochrane Database Syst. Rev. 2000 CD001526
56. F. Labrie, A. Bélanger, L. Cusan, J. Simard, V. Luu-The, C. Labrie, J.L. Gomez, P. Diamond, and B. Candas History of LHRH agonists and combination therapy in prostate cancer Endocr. Relat. Cancer 3 1996 243 278
57. F. Labrie, L. Cusan, J.L. Gomez, P. Diamond, and A. Bélanger Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer Mol. Urol. 1 1997 253 261
58. F. Labrie, A. Dupont, R. Suburu, L. Cusan, M. Tremblay, J.L. Gomez, and J. Emond Serum prostate specific antigen (PSA) as prescreening test for prostate cancer J. Urol. 147 1992 846 852
59. F. Labrie, B. Candas, L. Cusan, J.L. Gomez, P. Diamond, R. Suburu, and M. Lemay Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen Urology 47 1996 212 217
60. F. Lee, S.T. Torp-Pedersen, D.B. Siders, P.J. Littrup, and R.D. McLeary Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma Radiology 170 1989 609 615
61. F. Labrie, L. Cusan, J.L. Gomez, P. Diamond, R. Suburu, M. Lemay, B. Tetu, Y. Fradet, and B. Candas Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist Urology 44 6A 1994 29 37
62. J. Laverdiere, J.L. Gomez, L. Cusan, R. Suburu, P. Diamond, M. Lemay, B. Candas, A. Fortin, and F. Labrie Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 37 1997 247 252
63. F. Labrie Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease Mol. Cell. Endocrinol. 198 2002 77 87
64. F. Labrie, B. Candas, J.L. Gomez, and L. Cusan Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 60 2002 115 119
65. B. Candas, L. Cusan, J.-L. Gomez, P. Diamond, R.E. Suburu, J. Lévesque, G. Brousseau, A. Bélanger, and F. Labrie Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer Prostate 45 2000 19 35
66. F.H. Shröder, P.V.D. Maas, P. Beemsterboer, A.B. Kruger, R. Hoedemaeker, and J. Rietbergen Evaluation of the digital rectal examination as a screening test for prostate cancer J. Natl. Cancer Inst. 1998 1817 1823
67. T. Makinen, T.L. Tammela, M. Hakama, U.H. Stenman, S. Rannikko, J. Aro, H. Juusela, L. Maattanen, and A. Auvinen Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng/ml: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests J. Urol. 166 2001 1339 1342
68. F.H. Shröder, M. Roobol-Bouts, A.N. Vis, T.V.D. Kwast, and R. Kranse Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination Urology 57 2001 83 90
69. J. Hugosson, G. Aus, C. Becker, S. Carlsson, H. Eriksson, H. Lilja, P. Lodding, and G. Tibblin Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden BJU Int. 85 2000 1078 1084
70. C.H. Bangma, R. Kranse, B.G. Blijenberg, and F.H. Schroder The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men Urology 46 1995 773 778
71. P. Lodding, G. Aus, S. Bergdahl, R. Frosing, H. Lilja, C.G. Pihl, and J. Hugosson Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. Prostate specific antigen J. Urol. 159 1998 899 903
72. C. Mettlin Early detection of prostate cancer following repeated examinations by multiple modalities: results of the American Cancer Society National Prostate Cancer Detection Project Clin. Invest. Med. 16 1993 440 447
73. American Cancer Society Surveillance Research, cancer facts and figures CA Cancer J. Clin. 2000 4 9
74. American Urological Association, Board of Directors Report: Early detection of prostate, American Urological Association March, 2001.
75. F. Labrie, B. Candas, A. Dupont, L. Cusan, J.L. Gomez, R.E. Suburu, P. Diamond, J. Lévesque, and A. Bélanger Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial Prostate 38 1999 83 91
76. F. Labrie, L. Cusan, J.L. Gomez, A. Bélanger, G. Brousseau, J. Lévesque, and B. Candas Screening decreases prostate cancer mortality: 11-year follow-up on the 1988 Quebec prospective randomized controlled trial Prostate 59 2004 311 318
77. G. Bartsch, W. Horninger, H. Klocker, W. Oberaigner, G. Severi, C. Robertson, and P. Boyle Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria. AUA Annual Meeting J. Urol. 163 2000 88 (Abst. 387)
78. F. Labrie, J. Cusan, J. Gomez, Levesque, and B. Candas Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening Aging Male 2 1999 33 43
79. B. Candas, F. Labrie, Unequal decrease of prostate cancer specific death rates through the Province of Quebec between 1991 and 1999, in: 14th Int. Symposium J. Steroid Biochem. Mol. Biol., Québec, Canada, 2000, p. 133 (Abst. 86-P).
80. N. Faure, F. Labrie, A. Lemay, A. Bélanger, Y. Gourdeau, B. Laroche, and G. Robert Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (GNRH) agonist in adult men Fertil. Steril. 37 1982 416 424
81. G. Tolis, D. Ackman, A. Stellos, A. Mehta, F. Labrie, A.T.A. Fazekas, A.M. Comaru-Schally, and A.V. Schally Tumor growth inhibition in patients with prostatic carcinoma treated with LHRH agonists Proc. Natl. Acad. Sci. 79 1982 1658 1662
82. C. Huggins, and C.V. Hodges Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate Cancer Res. 1 1941 293 307
83. VACURG Treatment and survival of patients with cancer of the prostate Surg. Gynecol. Obstet. 124 1967 1011 1017
84. M.R. Robinson, and B.S. Thomas Effect of hormone therapy on plasma testosterone levels in prostatic cancer Br. Med. J. 4 1971 391 394
85. W.B. Peeling Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma Urology 33 1989 45 52
86. G. Kolata Prostate cancer consensus hampered by lack of data Science 236 1987 1626 1627
87. R.G. Middleton, I.M. Thompson, M.S. Austenfeld, W.H. Cooner, R.J. Correa, R.P. Gibbons, H.C. Miller, J.E. Oesterling, M.I. Resnick, and S.R. Smalley Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association J. Urol. 154 1995 2144 2148
88. M. Bolla, D. Gonzalez, P. Warde, J.B. Dubois, R.O. Mirimanoff, G. Storme, J. Bernier, A. Kuten, C. Sternberg, T. Gil, L. Collette, and M. Pierart Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N. Engl. J. Med. 337 1997 295 300
89. M.V. Pilepich, R. Caplan, R.W. Byhardt, C.A. Lawton, M.J. Gallagher, J.B. Mesic, G.E. Hanks, C.T. Coughlin, A. Porter, W.U. Shipley, and D. Grignon Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31 J. Clin. Oncol. 15 1997 1013 1021
90. G.E. Hanks, J. Lu, M. Machtay, V. Venkatesan, W. Pinover, R. Byhardt, and S.A. Rosenthal RTOG Protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate 36th Annual Meeting of the American Society of Clinical Oncology New Orleans, LA, USA 2000 1284
91. T. Granfors, H. Modig, J.E. Damber, and R. Tomic Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study J. Urol. 159 1998 2030 2034
92. E.M. Messing, J. Manola, M. Sarosdy, G. Wilding, E.D. Crawford, and D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N. Engl. J. Med. 341 1999 1781 1788
93. H. Akaza, Y. Homma, K. Okada, M. Yokoyama, M. Usami, Y. Hirao, T. Tsushima, Y. Ohashi, and Y. Aso A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up BJU Int. 91 2003 33 36
94. M.K. Brawer, E.D. Crawford, F. Labrie, A. Mendoza-Valdez, P.D. Miller, and D.P. Petrylak Androgen deprivation and other treatments for advanced prostate cancer Rev. Urol. 3 2001 S59 S68
95. R. Peto, O. Dalesio, Breast and prostate cancer: 10-year survival gains in the hormonal adjuvant treatment trials, in: ECCO 12, Copenhagen, Eur. J. Cancer (2003) S101.
96. C. Arnst Why did prostate cancer death rates fall? Business Week 2003
97. F. Labrie Prostate cancer and combined androgen blockade at all stages of disease D. Khayat G.N. Hortobagyi Progress in Anti-Cancer Chemotherapy 2000 Springer France, Berlin, Heidelberg 171-187
98. F. Labrie Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support Prostate 43 2000 215 222
99. L. Vaillancourt, B. Têtu, Y. Fradet, A. Dupont, J. Gomez, L. Cusan, E.R. Suburu, P. Diamond, B. Candas, and F. Labrie Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma Am. J. Surg. Pathol. 20 1996 86 93
100. T.H. van der Kwast, B. Têtu, B. Candas, J.L. Gomez, L. Cusan, and F. Labrie Prolongued neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy Urology 53 1999 523 529
101. F. Labrie, L. Cusan, J.L. Gomez, A. Belanger, and B. Candas Long-term combined androgen blockade alone for localized prostate cancer Mol. Urol. 3 1999 217 225
102. J. Roy, S. Couillard, M. Gutman, and F. Labrie A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice Breast Cancer Res. Treat. 81 2003 223 229
103. T.H. van der Kwast, B. Tetu, B. Candas, J.L. Gomez, L. Cusan, and F. Labrie Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy Urology 53 1999 523 529
104. D. Mittan, S. Lee, E. Miller, R.C. Perez, J.W. Basler, and J.M. Bruder Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs J. Clin. Endocrinol. Metab. 87 2002 3656 3661
105. H.W. Daniell Osteoporosis due to androgen deprivation therapy in men with prostate cancer Urology 58 2001 101 107
106. L. Cusan, J.L. Gomez, B. Candas, P. Diamond, and F. Labrie The effect of long term combined androgen blockade (CAB) (LHRH-A and a pure antiandrogen) on bone mineral density (BMD) in patients suffering from localized and advanced prostate cancer (PC) The 94th Annual Meeting of the American Urological Association Dallas, TX, USA 1999
107. F. Labrie Endocrine-sensitive cancers of the prostate and breast J. Baxter S. Melmed M.I. New Genetics in Endocrinology 2002 Lippincott-William and Wilkins 607 661